Physician profile
Sandra E Lemming
NPI 1508861600
$592.53
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $130 · 2021: $13.62.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $213.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $118.16 | 2019 | |
| Sanofi-Aventis U.S. LLC | $54.90 | 2020 | |
| Pfizer INC. | $50.73 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $47.57 | 2019 | |
| Merck Sharp & Dohme LLC | $22.74 | 2019-2020 | |
| Glaxosmithkline, LLC. | $15.78 | 2020 | |
| Optinose US, INC. | $15.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.91 | 2019 | |
| Novo Nordisk INC | $13.63 | 2019 | |
| Dexcom, INC. | $13.62 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Lemming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.